IMAC Holdings Announces Leadership Succession
May 24 2024 - 9:00AM
IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) today
announced leadership transitions to the board of directors and
executive team. Faith Zaslavsky has been appointed chief executive
officer, succeeding Jeff Ervin, to lead newly acquired assets in
the proteomics and precision medicine industry.
“I am excited and honored to join IMAC and
continue the mission that Jeff and team created, which is focused
on providing better outcomes for patients,” said Ms. Zaslavsky. “In
the 23 years of working in the genomic space, I have never been
more excited about a product and the brilliant and dynamic
individuals who have worked hard to bring this cutting-edge
technology to patients and providers. Our technology and the people
behind it create a game changing advancement in precision medicine
by providing physicians the ability to create a highly specific and
personalized treatment plan for patients facing the cancer
journey.”
Ms. Zaslavsky previously served as COO and CEO
at Theralink Technologies. Prior to Theralink, Ms. Zaslavsky served
as President of Oncology for Myriad Genetics. Her responsibilities
have included overseeing all commercials functions which include
leading Medical Services, Medical Affairs, National and Enterprise
Accounts, and Sales and Marketing. She has spent 23 years leading
and transforming teams, designing solutions for physicians to
support care, and advocating for patients facing a journey with
cancer. She also serves on the American Society of Breast Surgeons
Foundation Board of Directors.
The RPPA technology acquired has proven through
multiple clinical trials to be a superior indicator of the presence
of key biomarkers associated with drug selection in Breast Cancer
and other cancers. BACK is poised to continue the progress of this
technology and establish RPPA as an essential test for all breast
cancer patients and many other cancers and other conditions in the
near future.
“IMAC has delivered innovative treatments for
predictable and safe outcomes to patients since its inception, and
I am excited that will continue in the oncology specialty for
physicians seeking optimal care for patients with advanced breast
cancer,” said Mr. Ervin. “Faith has a tremendous passion for
patients and the experience to lead this exceptional technology
into commercialization.”
The board of directors will consist of three
independent board members effective today. The board accepted the
resignation of BACK co-founders Dr. Matt Wallis and Mr. Ervin from
the board. Mr. Ervin will serve as a transition consultant.
About IMAC Holdings, Inc.
IMAC Holdings, Inc. is a clinical research and
commercialization company. The Company is focused on innovative
medical advancements and care in the oncology and neurological
medical specialties. The Company's technology, through its patented
phosphoprotein and protein biomarker platform and lab developed
tests (LDTs), targets multiple areas of oncology and drug
development. Its LDTs are utilized by oncologists in the United
States to assist in delivering a targeted treatment plan for their
patients with advanced breast cancer. For more information visit
www.imacholdings.com.
###
IMAC Investor Contact:sgardzina@imacholdings.com
IMAC (NASDAQ:BACK)
Historical Stock Chart
From Jul 2024 to Aug 2024
IMAC (NASDAQ:BACK)
Historical Stock Chart
From Aug 2023 to Aug 2024